These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 348073

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical aspects of drug resistance.
    Holland JF.
    Antibiot Chemother (1971); 1978; 23():238-46. PubMed ID: 348082
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New molecular targets for anticancer therapy. The First International Conference on New Molecular Targets for Anticancer Therapy. Naples, Italy. June 22-23 1998.
    Normanno N, Agrawal S.
    Mol Med Today; 1998 Dec; 4(12):514-6. PubMed ID: 9866820
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
    Skladanowski A, Bozko P, Sabisz M.
    Chem Rev; 2009 Jul; 109(7):2951-73. PubMed ID: 19522503
    [No Abstract] [Full Text] [Related]

  • 7. Targeting Cancer Metabolism and Cell Cycle by Plant-Derived Compounds.
    Çoban EA, Tecimel D, Şahin F, Deniz AAH.
    Adv Exp Med Biol; 2020 Jul; 1247():125-134. PubMed ID: 31749136
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic potential of targeting the cell cycle.
    Webster KR.
    Chem Res Toxicol; 2000 Oct; 13(10):940-3. PubMed ID: 11080037
    [No Abstract] [Full Text] [Related]

  • 9. American Association for Cancer Research--96th Annual Meeting. Targeting the cell cycle and HDAC inhibitors.
    Phillips T, Collins T, Davies J.
    IDrugs; 2005 Jun; 8(6):450-3. PubMed ID: 15906184
    [No Abstract] [Full Text] [Related]

  • 10. Bibliography. Current world literature. Therapeutic modalities.
    Curr Opin Oncol; 2001 Nov; 13(6):B172-92. PubMed ID: 11708263
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The use of cell kinetics in the development of drug combinations.
    Valeriote FA.
    Pharmacol Ther; 1979 Nov; 4(1):1-33. PubMed ID: 461499
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model.
    Florian JA, Eiseman JL, Parker RS.
    Comput Biol Med; 2008 Mar; 38(3):339-47. PubMed ID: 18222419
    [Abstract] [Full Text] [Related]

  • 15. The contribution of age structure to cell population responses to targeted therapeutics.
    Gabriel P, Garbett SP, Quaranta V, Tyson DR, Webb GF.
    J Theor Biol; 2012 Oct 21; 311():19-27. PubMed ID: 22796330
    [Abstract] [Full Text] [Related]

  • 16. Complex regulation of telomerase activity: implications for cancer therapy.
    Elenitoba-Johnson KS.
    Am J Pathol; 2001 Aug 21; 159(2):405-10. PubMed ID: 11485897
    [No Abstract] [Full Text] [Related]

  • 17. [Principles of chemotherapy of neoplastic diseases in children].
    Matysiak M, Ochocka M.
    Pediatr Pol; 1982 Dec 21; 57(12):1099-105. PubMed ID: 7182789
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 1999 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development, and Clinical Validation. Washington, DC, USA. November 16-19, 1999. Abstracts.
    Clin Cancer Res; 1999 Nov 21; 5(11 Suppl):3729s-3897s. PubMed ID: 10590781
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.